User:Coloradochromatography/sandbox

H2-CBD

H2CBD, or hydrogenated CBD, was first accessed by the Todd group in 1940 by catalytic hydrogenation of cannabidiol. Gallily et al accessed the dihydro-cannabidiol H2CBD in 2006 following testing demonstrating binding affinity to CB1 receptor and their anti-inflammatory capacity. Scialdone treated U87 cells with hydrogenated CBD in mouse models and saw a reduction in tumor weight over a 48-h period.